Galapagos NV (GLPG)
undefined
undefined%
At close: undefined
26.82
0.22%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need.

Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.

The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis.

The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.

Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV
Galapagos NV logo
Country BE
IPO Date Feb 27, 2012
Industry Biotechnology
Sector Healthcare
Employees 1,123
CEO Dr. Paulus A. Stoffels M.D., Ph.D.

Contact Details

Address:
Generaal De Wittelaan L11 A3
Mechelen,
BE
Website https://www.glpg.com

Stock Details

Ticker Symbol GLPG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001421876
CUSIP Number 36315X101
ISIN Number US36315X1019
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Paulus A. Stoffels M.D., Ph.D. Chief Executive Officer, Chairman, Interim Head of R&D
Thad Huston C.M.A. Executive Vice President, Chief Financial Officer & Chief Operating Officer
Alice Dietrich Head of Medical Affairs
Annelies Missotten Executive Vice President & Chief Human Resources Officer
Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D. Head of Small Molecules Discovery & Senior Vice President
Ellen Van Der Aar Head of Development
Marieke Vermeersch Head of Corporate Communication
Philippe Alen M.B.A., Ph.D., Pharm.D. Senior Vice President & Head of Business Development
Sofie Van Gijsel Head of Investor Relations
Valeria Cnossen Executive Vice President & General Counsel

Latest SEC Filings

Date Type Title
Dec 09, 2024 6-K Filing
Nov 20, 2024 S-8 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 06, 2024 6-K Filing
Oct 31, 2024 6-K Filing
Oct 08, 2024 SC 13D/A [Amend] Filing
Oct 07, 2024 6-K Filing
Sep 30, 2024 6-K Filing
Sep 16, 2024 6-K Filing
Sep 03, 2024 6-K Filing